论文部分内容阅读
肿瘤的生长和转移离不开肿瘤新生血管,这使得抗血管形成治疗成为肿瘤治疗的重要途径之一。血管内皮生长因子及其受体是抗肿瘤治疗的重要靶点之一。本文主要介绍了近年来抗血管形成治疗的一些最新药物研究成果——包括针对血管内皮生长因子的单克隆抗体——贝伐;针对血管内皮生长因子受体的酪氨酸激酶抑制剂——舒尼替尼、索拉非尼等;以及血管内皮生长因子受体的单克隆抗体IMC-1C11等。
Tumor growth and metastasis can not be separated from tumor neovascularization, which makes anti-angiogenesis therapy become an important way of cancer treatment. Vascular endothelial growth factor and its receptor is one of the important targets of anti-tumor therapy. This article describes some of the latest anti-angiogenic drugs in recent years, the results of the study - including vascular endothelial growth factor monoclonal antibody - bevac; vascular endothelial growth factor receptor tyrosine kinase inhibitor Shu Nitinib, sorafenib and the like; and monoclonal antibody IMC-1C11 of vascular endothelial growth factor receptor and the like.